$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2014 Q3 Form 10-Q Financial Statement

#000119312514301873 Filed on August 08, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $11.00M $7.300M $8.700M
YoY Change 22.22% -16.09% -58.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.900M $11.50M $5.800M
YoY Change 45.59% 98.28% -48.21%
% of Gross Profit
Research & Development $46.27M $44.67M $24.22M
YoY Change 34.29% 84.48% 11.47%
% of Gross Profit
Depreciation & Amortization $3.100M $2.900M $2.700M
YoY Change 10.71% 7.41% 3.85%
% of Gross Profit
Operating Expenses $56.17M $52.30M $30.00M
YoY Change 36.25% 74.34% -8.96%
Operating Profit -$45.20M -$45.01M -$21.31M
YoY Change 40.22% 111.17% 76.61%
Interest Expense $800.0K $700.0K $300.0K
YoY Change 166.67% 133.33% -133.33%
% of Operating Profit
Other Income/Expense, Net $1.277M $616.0K $259.0K
YoY Change 359.35% 137.84% -129.13%
Pretax Income -$43.92M -$44.39M -$21.05M
YoY Change 37.45% 110.84% 62.5%
Income Tax $100.0K -$300.0K -$2.884M
% Of Pretax Income
Net Earnings -$43.99M -$44.07M -$18.17M
YoY Change 48.18% 142.58% 40.24%
Net Earnings / Revenue -399.9% -603.75% -208.84%
Basic Earnings Per Share
Diluted Earnings Per Share -$575.9K -$581.8K -$295.0K
COMMON SHARES
Basic Shares Outstanding 76.35M shares 75.55M shares 62.17M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $590.6M $605.3M $209.7M
YoY Change 204.8% 188.66% -8.43%
Cash & Equivalents $82.72M $80.73M $24.98M
Short-Term Investments $507.9M $524.6M $184.7M
Other Short-Term Assets $10.70M $10.30M $4.200M
YoY Change 122.92% 145.24% -39.13%
Inventory
Prepaid Expenses
Receivables $400.0K $100.0K $500.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $643.0M $665.1M $214.4M
YoY Change 222.86% 210.28% -10.8%
LONG-TERM ASSETS
Property, Plant & Equipment $18.81M $16.95M $18.05M
YoY Change 10.79% -6.05% 27.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $324.5M $350.6M $230.2M
YoY Change 40.23% 52.3% 261.38%
Other Assets
YoY Change
Total Long-Term Assets $343.3M $367.5M $248.2M
YoY Change 38.25% 48.08% 217.39%
TOTAL ASSETS
Total Short-Term Assets $643.0M $665.1M $214.4M
Total Long-Term Assets $343.3M $367.5M $248.2M
Total Assets $986.4M $1.033B $462.6M
YoY Change 120.41% 123.25% 45.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.201M $6.168M $4.534M
YoY Change 90.65% 36.04% -17.56%
Accrued Expenses $19.80M $15.78M $8.488M
YoY Change 28.68% 85.94% -40.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $56.85M $53.75M $53.07M
YoY Change 3.56% 1.28% -7.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $500.0K $1.000M $101.3M
YoY Change -99.47% -99.01% 38.58%
Total Long-Term Liabilities $500.0K $1.000M $101.3M
YoY Change -99.47% -99.01% 38.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.85M $53.75M $53.07M
Total Long-Term Liabilities $500.0K $1.000M $101.3M
Total Liabilities $81.88M $90.39M $154.4M
YoY Change -45.39% -41.45% 18.57%
SHAREHOLDERS EQUITY
Retained Earnings -$935.2M -$891.3M -$534.2M
YoY Change 65.86% 66.84%
Common Stock $1.825B $1.812B $814.2M
YoY Change 118.69% 122.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $904.5M $942.3M $308.2M
YoY Change
Total Liabilities & Shareholders Equity $986.4M $1.033B $462.6M
YoY Change 120.41% 123.25% 45.23%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$43.99M -$44.07M -$18.17M
YoY Change 48.18% 142.58% 40.24%
Depreciation, Depletion And Amortization $3.100M $2.900M $2.700M
YoY Change 10.71% 7.41% 3.85%
Cash From Operating Activities -$40.70M -$46.60M -$23.60M
YoY Change 87.56% 97.46% 8.76%
INVESTING ACTIVITIES
Capital Expenditures -$3.200M -$1.800M -$400.0K
YoY Change 255.56% 350.0% -75.0%
Acquisitions
YoY Change
Other Investing Activities $41.10M -$226.5M -$52.90M
YoY Change -2840.0% 328.17% -675.0%
Cash From Investing Activities $38.00M -$228.4M -$53.20M
YoY Change -1561.54% 329.32% -800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.800M 5.100M 4.000M
YoY Change -56.76% 27.5% 566.67%
NET CHANGE
Cash From Operating Activities -40.70M -46.60M -23.60M
Cash From Investing Activities 38.00M -228.4M -53.20M
Cash From Financing Activities 4.800M 5.100M 4.000M
Net Change In Cash 2.100M -269.9M -72.80M
YoY Change -115.91% 270.74% 439.26%
FREE CASH FLOW
Cash From Operating Activities -$40.70M -$46.60M -$23.60M
Capital Expenditures -$3.200M -$1.800M -$400.0K
Free Cash Flow -$37.50M -$44.80M -$23.20M
YoY Change 80.29% 93.1% 15.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
20.13
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76354817 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24975000
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76324130 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76324130 shares
CY2014Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
32548000
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
53745000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21983000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6168000
CY2014Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
942269000
CY2014Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1810775000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-891252000
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
27002000
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15783000
CY2014Q2 us-gaap Liabilities
Liabilities
90390000
CY2014Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3097000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
763000
CY2014Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
711000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1032659000
CY2014Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
524585000
CY2014Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
350585000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16953000
CY2014Q2 us-gaap Assets
Assets
1032659000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80727000
CY2014Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
875314000
CY2014Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
875170000
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10270000
CY2014Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
89000
CY2014Q2 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
49450000
CY2014Q2 us-gaap Assets Current
AssetsCurrent
665121000
CY2014Q2 alny Net Rentable Area Under Lease
NetRentableAreaUnderLease
129000 sqft
CY2014Q2 alny Accrued Intraperiod Tax Allocation
AccruedIntraperiodTaxAllocation
4081000
CY2014Q2 alny Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
355000
CY2014Q2 alny Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
211000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51405000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-596235000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
32696000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14160000
CY2013Q4 us-gaap Liabilities
Liabilities
150183000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2925000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
637000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63741573 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63741573 shares
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
93394000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53864000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19717000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5896000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
270347000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
846228000
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1112000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
420530000
CY2013Q4 us-gaap Available For Sale Securities Equity Securities Noncurrent
AvailableForSaleSecuritiesEquitySecuritiesNoncurrent
45452000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
192701000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
104602000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16448000
CY2013Q4 us-gaap Assets
Assets
420530000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53169000
CY2013Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
297323000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
297303000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3910000
CY2013Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
4248000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
254028000
CY2013Q4 alny Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
86000
CY2013Q4 alny Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
66000
CY2014Q1 alny Research And Development Asset Acquired Through Other Than Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredThroughOtherThanBusinessCombinationWrittenOff
199300000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24573000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60424000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9171000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2178000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12051000
us-gaap Share Based Compensation
ShareBasedCompensation
6452000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-26430000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-184049000
us-gaap Operating Expenses
OperatingExpenses
58445000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1095000
us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-3446000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
27329000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12468000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
274428000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30628000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
us-gaap Investment Income Net
InvestmentIncomeNet
494000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1650000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14714000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-247000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31116000
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-192000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
356000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
488000
us-gaap Net Income Loss
NetIncomeLoss
-27182000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3043000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
182192000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
470000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
173572000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4838000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
92557000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46394000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8620000
dei Trading Symbol
TradingSymbol
ALNY
dei Entity Registrant Name
EntityRegistrantName
ALNYLAM PHARMACEUTICALS, INC.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001178670
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8061000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-88300000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71833000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Use of Estimates</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect&#xA0;the reported amounts of assets and liabilities and&#xA0;the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and&#xA0;the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.11
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2240000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
15570000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2266000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
768510000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-313202000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-159000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
15703000
us-gaap Investment Income Net
InvestmentIncomeNet
1026000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6360000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-292751000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-332000
us-gaap Operating Income Loss
OperatingIncomeLoss
-314069000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
25000000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-4159000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
867000
us-gaap Net Income Loss
NetIncomeLoss
-295017000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2235000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
723037000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
724013000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20443000
us-gaap Share Based Compensation
ShareBasedCompensation
13271000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
27558000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-608155000
us-gaap Operating Expenses
OperatingExpenses
329639000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-15090000
us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-18185000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
121000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5468000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
187595000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88430000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
16679000
alny Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2016-09
alny Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P90D
alny Investment Maturity Period Minimum
InvestmentMaturityPeriodMinimum
P90D
alny Research And Development Asset Acquired Through Other Than Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredThroughOtherThanBusinessCombinationWrittenOff
220766000
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9200000 shares
CY2013Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
11600000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
173600000
CY2014Q1 alny Extended Lease Expiration Date
ExtendedLeaseExpirationDate
2021-09-30
CY2014Q1 alny Lease Extension Period
LeaseExtensionPeriod
P5Y
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61661000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2013Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
8687000
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7309000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21053000
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2013Q2 us-gaap Investment Income Net
InvestmentIncomeNet
270000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10860000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21312000
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
259000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-18169000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5784000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
29999000
CY2013Q2 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-2884000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24215000
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75835000 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2014Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
7295000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3047000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44389000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-77000
CY2014Q2 us-gaap Investment Income Net
InvestmentIncomeNet
693000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47121000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-45005000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
616000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-44074000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11518000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
52300000
CY2014Q2 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-315000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44672000
CY2014Q2 alny Research And Development Asset Acquired Through Other Than Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredThroughOtherThanBusinessCombinationWrittenOff
-3890000

Files In Submission

Name View Source Status
0001193125-14-301873-index-headers.html Edgar Link pending
0001193125-14-301873-index.html Edgar Link pending
0001193125-14-301873.txt Edgar Link pending
0001193125-14-301873-xbrl.zip Edgar Link pending
alny-20140630.xml Edgar Link completed
alny-20140630.xsd Edgar Link pending
alny-20140630_cal.xml Edgar Link unprocessable
alny-20140630_def.xml Edgar Link unprocessable
alny-20140630_lab.xml Edgar Link unprocessable
alny-20140630_pre.xml Edgar Link unprocessable
d754022d10q.htm Edgar Link pending
d754022dex101.htm Edgar Link pending
d754022dex102.htm Edgar Link pending
d754022dex103.htm Edgar Link pending
d754022dex104.htm Edgar Link pending
d754022dex105.htm Edgar Link pending
d754022dex106.htm Edgar Link pending
d754022dex12.htm Edgar Link pending
d754022dex311.htm Edgar Link pending
d754022dex312.htm Edgar Link pending
d754022dex321.htm Edgar Link pending
d754022dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending